---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-024814"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T23:04:03.538834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026

## Summary
- Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.
- Topline results from the Phase 2b trial of ALTO-300 are expected in mid-2026.
- Company reported preliminary 2024 year-end cash of ~$168M, expected to fund operations into 2028.
- Interim analysis included 87 biomarker-positive patients after in-depth site and patient eligibility review.

## SEC filing metadata
- accession: 0001193125-25-024814
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/0001193125-25-024814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000119312525024814/d876505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-024814
- JSON: https://secwatch.observer/filing/0001193125-25-024814.json
- Plain text: https://secwatch.observer/filing/0001193125-25-024814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.